Authors
Latest:
The American Cancer Society, Winship Partner to Accelerate Cancer Research in GeorgiaThe American Cancer Society, in partnership with Winship Cancer Institute of Emory University, announced a new project that aims to significantly accelerate cancer research and improve patient outcomes.
Latest:
Future Directions for the Management of HR+ Breast CancerAndrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Latest:
Dr. Kahn on the Importance of Diverse Clinical Trial Participation in OncologyJustine Kahn, MD, MS, discusses the importance of diverse clinical trial participation within the oncology space.
Latest:
Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro NakamuraIn this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.
Latest:
Dr. Pollyea on the Role of Maintenance Therapy in AMLDan Pollyea, MD, MS, discusses the current role of maintenance therapy in patients with acute myeloid leukemia who are unfit for intensive chemotherapy.
Latest:
Dr Shusterman on a DNA Methylome Enrichment Platform for Early Detection of Solid TumorsMichael Shusterman, MD, discusses findings from a retrospective study to determine the feasibility of a novel genome-wide methylome enrichment platform for the early detection of multiple solid tumors.
Latest:
Dr Byndloss on the Relationship Between the Gut Microbiome and GI CancersMariana X. Byndloss, DVM, PhD, discusses how the gut microbiome influences human health, highlighting the relationship between the gut microbiome and a person’s risk for developing gastrointestinal cancers, as well as characteristics of a healthy gut microbiome.
Latest:
Expert Commentary: Insights into Cancer Mutation PatternsResearchers at Rutgers Cancer Institute of New Jersey provided commentary on how changes in the structure of DNA influence the mutation patterns in cancer.
Latest:
Dr Van Akkooi on the Prognostic Value of Minimal Sentinel Node Tumor Burden in MelanomaAlexander C. Van Akkooi, MD, PhD, FRACS, discusses the prognostic value of minimal sentinel node tumor burden in melanoma.
Latest:
Is War a Good Metaphor for Cancer Care?The National Cancer Act of 1971 introduced the concept of a “war on cancer,” which has since affected the language we use when discussing the disease.
Latest:
Combination Chemotherapy and Immunotherapy for Advanced NSCLCExperts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.
Latest:
Dr Pal on Outcomes With the Use of Zanzalintinib in Relapsed/Refractory ccRCCSumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.
Latest:
Dr Liu on Epigenetic Regulation of CD38/CD48 in Multiple MyelomaJiye Liu, PhD, discusses epigenetic regulation of CD38/CD48 in multiple myeloma.
Latest:
Dr. Samur on the Evolving Treatment Landscape in Multiple MyelomaMehmet K. Samur, PhD, discusses the evolving treatment landscape in multiple myeloma.
Latest:
Dr. Chmielowski on the Current Treatment Landscape of Metastatic MelanomaBartosz Chmielowski, MD, discusses the current treatment landscape of metastatic melanoma.
Latest:
Cetuximab–Radionuclide Functionalized Polymeric Nanocomplexes: A Radiopharmaceutical Perspective for Liver CancerLiver cancer is a highly vascularized and one of the most drug resistant forms of solid tumors.
Latest:
MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALLDoug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).
Latest:
Dr. Larocca on Recent Advancements in R/R Multiple MyelomaAlessandra Larocca, MD, PhD, discusses recent advancements in relapsed/refractory multiple myeloma.
Latest:
Dr. Dang on the Design of the BERENICE Trial in HER2+ Breast CancerChau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.
Latest:
Will Immunotherapy Become a Standard of Care for Glioblastoma?Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.
Latest:
Dr Fenton on Findings from the DESTINY-Breast02 Trial in HER2+ Breast CancerMary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.
Latest:
Dr Umemura on the Development of ONC201 in H3K27M-Mutant Diffuse Midline GliomaYoshie Umemura, MD, discusses the development of ONC201 in patients with H3K27M-mutated diffuse midline glioma.
Latest:
Dr Jain on the Importance of Novel Therapies in Pediatric Patients With Bleeding DisordersAkshat Jain, MBBS, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.
Latest:
Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug InteractionsDr Leif Stenke reviews data on XS004 in patients with chronic myeloid leukemia (CML) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.
Latest:
Dr. Anderson on Overcoming Suppressive Signals by Engineering T-cells in Ovarian CancerKristin G. Anderson, PhD, discusses overcoming suppressive signaling by engineering T-cells in ovarian cancer.
Latest:
Dr Qin on Upcoming Areas of Interest in RCC ResearchQian (Janie) Qin, MD, discusses upcoming areas of interest in the renal cell carcinoma armamentarium.
Latest:
Dr Cherng on Considerations for the Use of Bispecific Antibodies in DLBCLHua-Jay “Jeff” Cherng, MD, discusses efficacy and safety considerations for the use of bispecific antibodies in patients with DLBCL.
Latest:
Dr Ashraf on the Utility of T-DXd in HER2-Mutated NSCLCNoman Ashraf, MD, discusses notable data seen with T-DXd treatment in previously treated HER2-mutated and -overexpressing non–small cell lung cancer.
